Summit Therapeutics Inc.
SMMT | NASDAQ
$17.07
+$0.17 (+1.01%)
Sep 22, 2026, 12:31 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | 583.19K | 1.34M | 628.88K |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | 583.19K | 1.34M | 628.88K |
Operating Income | -1.09B | -180.51M | -478.23M | -59.63M | -63.73M | -71.65M |
Interest Income | 15.5M | 13.47M | 10.4M | 1.51M | n/a | 4K |
Pretax Income | -1.08B | -176.77M | -482.37M | -65.17M | -65.52M | -62.27M |
Net Income | -1.08B | -176.77M | -482.37M | -65.17M | -65.52M | -38.53M |
Selling & General & Admin | 556.7M | 48.35M | 23.74M | 22.12M | 17.46M | 14.06M |
Research & Development | 537.67M | 132.42M | 455.27M | 43.01M | 63.12M | 38.96M |
Other Expenses | n/a | -250.34K | -785.77K | -4.92M | -15.51M | -13.49M |
Operating Expenses | 1.09B | 180.51M | 478.23M | 60.22M | 65.07M | 39.53M |
Interest Expense | n/a | 8.69M | 16.46M | 4.4M | 208.3K | 255K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.09B | 180.51M | 478.23M | 60.22M | 65.07M | 39.53M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | -9.58M |
Shares Outstanding (Basic) | 747.7M | 713.92M | 619.65M | 192.15M | 92.24M | 69.34M |
Shares Outstanding (Diluted) | 747.7M | 718.54M | 619.65M | 193.34M | 92.24M | 69.52M |
EPS (Basic) | -1.44 | -0.25 | -0.78 | -0.34 | -0.71 | -0.55 |
EPS (Diluted) | -1.44 | -0.25 | -0.78 | -0.34 | -0.71 | -0.56 |
EBITDA | -1.08B | -168.46M | -69.45M | -51.58M | -64.31M | -37.13M |
EBIT | -1.08B | -168.53M | -69.61M | -52.63M | -65.31M | -38.27M |
Depreciation & Amortization | 146K | 71K | 155.32K | 1.04M | 996.07K | 1.13M |
Add to Watchlist
Select watchlists to add or remove SMMT